Lichtnekert Julia, Anders Hans-Joachim, Lech Maciej
Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, München, Germany.
J Inflamm Res. 2022 Dec 2;15:6533-6552. doi: 10.2147/JIR.S363722. eCollection 2022.
Lupus nephritis is a severe organ manifestation of systemic lupus erythematosus, and its pathogenesis involves complex etiology and mechanisms. Despite significant knowledge gains and extensive efforts put into understanding the development and relapsing disease activity, lupus nephritis remains a substantial cause of morbidity and mortality in lupus patients. Current therapies retain a significant unmet medical need regarding rates of complete response, preventing relapse of lupus nephritis, progression of chronic kidney disease to kidney failure, drug toxicity, and pill burden-related drug non-adherence. Connected to progression of chronic kidney disease are the associated risks for disabling or even lethal cardiovascular events, as well as chronic kidney disease-related secondary immunodeficiency and serious infections. In this regard, biomarkers are needed that can predict treatment response to specific drugs to enable personalized precision medicine. A series of clinical trials with innovative immunomodulatory drugs are ongoing and raise expectations for improvements in the management of lupus nephritis. Here, we review how new developments in pathogenesis connect with current and future perspectives for the management of lupus nephritis.
狼疮性肾炎是系统性红斑狼疮的一种严重器官表现,其发病机制涉及复杂的病因和机制。尽管在了解疾病发展和复发活动方面取得了显著进展并付出了巨大努力,但狼疮性肾炎仍然是狼疮患者发病和死亡的主要原因。在完全缓解率、预防狼疮性肾炎复发、慢性肾脏病进展至肾衰竭、药物毒性以及与服药负担相关的药物不依从性方面,目前的治疗仍存在重大未满足的医疗需求。与慢性肾脏病进展相关的是致残甚至致命的心血管事件风险,以及慢性肾脏病相关的继发性免疫缺陷和严重感染。在这方面,需要能够预测对特定药物治疗反应的生物标志物,以实现个性化精准医疗。一系列使用创新免疫调节药物的临床试验正在进行中,人们对狼疮性肾炎治疗的改善寄予厚望。在此,我们综述发病机制的新进展如何与狼疮性肾炎治疗的当前和未来观点相联系。